人用狂犬疫苗的“暴利时代”已经过去，价格战之下，又有疫苗企业面临出售。7月21日，疫苗领域上市企业成都康华生物（300841.SZ）发布最新公告，上海生物医药产业并购基金（以下简称“并购基金”）拟通过协议方式收购康华生物，公司股票今日开市复盘。激烈竞争下的选择国内首家生产人二倍体细胞狂犬病疫苗的企业，也竞争不下去了。7月14日，康华生物股票开始停牌，理由是控股股东、实际控制人王振滔正筹划公司控制权...
Source Link人用狂犬疫苗的“暴利时代”已经过去，价格战之下，又有疫苗企业面临出售。7月21日，疫苗领域上市企业成都康华生物（300841.SZ）发布最新公告，上海生物医药产业并购基金（以下简称“并购基金”）拟通过协议方式收购康华生物，公司股票今日开市复盘。激烈竞争下的选择国内首家生产人二倍体细胞狂犬病疫苗的企业，也竞争不下去了。7月14日，康华生物股票开始停牌，理由是控股股东、实际控制人王振滔正筹划公司控制权...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.